GlassScriptPhysician profile
Julie A Romeis
NPI 1033756598
$45,696.77
in general payments reported to CMS, 2019-2025
30 companies · $34K in 2025
The $34K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,399 · 2022: $1,885 · 2023: $4,989 · 2024: $3,217 · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Honoraria: $11K · Food and Beverage: $9,998 · Consulting Fee: $2,500 · Travel and Lodging: $2,192 · Gift: $1,414 · Education: $83.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,288.00 |
| Honoraria | $10,937.50 |
| Food and Beverage | $9,998.14 |
| Consulting Fee | $2,500.00 |
| Travel and Lodging | $2,192.33 |
| Gift | $1,413.84 |
| Education | $83.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $15,220.17 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $13,531.67 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $6,447.54 | 2021-2025 | Caplyta |
| Abbvie INC. | $2,603.77 | 2021-2025 | |
| Alkermes, INC. | $1,535.26 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Uswm, LLC | $1,479.64 | 2022-2024 | Zimhi, Lucemyra |
| Teva Pharmaceuticals USA, INC. | $1,441.08 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,304.33 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $738.57 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $220.78 | 2024-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $174.77 | 2023-2025 | Quviviq, Quviviq |
| E.R. Squibb & Sons, L.L.C. | $131.64 | 2025 | Cobenfy |
| Indivior INC. | $125.35 | 2021-2025 | Sublocade |
| Bayer Healthcare Pharmaceuticals INC. | $117.14 | 2025 | |
| Lundbeck LLC | $101.35 | 2021-2024 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $90.99 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.32 | 2021-2025 | Trintellix |
| Neos Therapeutics, LP | $73.97 | 2022-2024 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $62.08 | 2023-2025 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $37.92 | 2023-2024 | Xelstrym |
| Livanova USA, INC. | $21.61 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Eisai INC. | $19.49 | 2021 | |
| Brainsway USA INC | $18.82 | 2023 | |
| Orexo US, INC. | $18.56 | 2022 | |
| Lilly USA, LLC | $16.77 | 2023 | Amyvid |
| Tms Neurohealth Centers INC. | $16.64 | 2025 | Tms Neurohealth Centers INC. |
| Collegium Pharmaceutical, INC. | $14.95 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $14.54 | 2024 | |
| Tris Pharma INC | $14.11 | 2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $12.94 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Romeis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.